Document is current

Any future updates will be listed below

Correction to: Is the Availability of Biosimilar Adalimumab Associated with Budget Saving? A Difference-in-Difference Analysis of 14 Countries

Crossref DOI link: https://doi.org/10.1007/s40259-024-00645-6

Published Online: 2024-01-22

Published Print: 2024-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark